ECSP078058A - Nuevas glicinamidas sustituidas, su preparación y su uso como medicamentos - Google Patents

Nuevas glicinamidas sustituidas, su preparación y su uso como medicamentos

Info

Publication number
ECSP078058A
ECSP078058A EC2007008058A ECSP078058A ECSP078058A EC SP078058 A ECSP078058 A EC SP078058A EC 2007008058 A EC2007008058 A EC 2007008058A EC SP078058 A ECSP078058 A EC SP078058A EC SP078058 A ECSP078058 A EC SP078058A
Authority
EC
Ecuador
Prior art keywords
glicinamids
medicines
preparation
new substituted
salts
Prior art date
Application number
EC2007008058A
Other languages
English (en)
Inventor
Kai Gerlach
Roland Pfau
Henning Priepke
Wolfgang Wienen
Annette Maria Schuler-Metz
Georg Dahmann
Herbert Nar
Sandra Ruth Handschuh
Original Assignee
Boehringer Ingelheim International Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International Gmbh filed Critical Boehringer Ingelheim International Gmbh
Publication of ECSP078058A publication Critical patent/ECSP078058A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Objeto de la presente invención son nuevas glicinamidas sustituidas de la fórmula general (I) (I)en las cuales D, M, R3, R4 y R5 están definidos como en la memoria descriptiva, sus tautómeros, sus enantiómeros, sus diastereoisómeros, sus mezclas y sus sales, en particular sus sales fisiológicamente compatibles con ácidos o bases inorgánicos u orgánicos, los cuales presentan valiosas propiedades.
EC2007008058A 2005-06-30 2007-12-27 Nuevas glicinamidas sustituidas, su preparación y su uso como medicamentos ECSP078058A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05014270 2005-06-30

Publications (1)

Publication Number Publication Date
ECSP078058A true ECSP078058A (es) 2008-01-23

Family

ID=35907001

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2007008058A ECSP078058A (es) 2005-06-30 2007-12-27 Nuevas glicinamidas sustituidas, su preparación y su uso como medicamentos

Country Status (32)

Country Link
US (3) US20100216769A1 (es)
EP (1) EP1899330B9 (es)
JP (1) JP4768016B2 (es)
KR (1) KR101321722B1 (es)
CN (1) CN101213195B (es)
AR (1) AR054627A1 (es)
AT (1) ATE489381T1 (es)
AU (1) AU2006265216B2 (es)
BR (1) BRPI0612580A8 (es)
CA (1) CA2613059C (es)
CY (1) CY1111627T1 (es)
DE (1) DE502006008392D1 (es)
DK (1) DK1899330T3 (es)
EA (1) EA015188B1 (es)
EC (1) ECSP078058A (es)
ES (1) ES2357029T3 (es)
HR (1) HRP20110044T2 (es)
IL (1) IL188323A (es)
MX (1) MX2007016253A (es)
MY (1) MY145883A (es)
NO (1) NO340670B1 (es)
NZ (1) NZ565440A (es)
PE (1) PE20070171A1 (es)
PL (1) PL1899330T3 (es)
PT (1) PT1899330E (es)
RS (1) RS51572B (es)
SG (1) SG163540A1 (es)
SI (1) SI1899330T1 (es)
TW (1) TWI392495B (es)
UA (1) UA94910C2 (es)
WO (1) WO2007003536A1 (es)
ZA (1) ZA200708525B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2582235A1 (en) 2004-10-04 2006-04-20 Millennium Pharmaceuticals, Inc. Lactam compounds useful as protein kinase inhibitors
PE20080145A1 (es) 2006-03-21 2008-02-11 Janssen Pharmaceutica Nv Tetrahidro-pirimidoazepinas como moduladores de trpv1
WO2008009125A1 (en) * 2006-07-20 2008-01-24 Cascade Therapeutics Inc. Tetrahydro-5h-pyrido[2,3-d]azepines as 5-ht2c ligands
PE20081834A1 (es) * 2006-12-31 2009-01-16 Boehringer Ingelheim Int Proceso para la sintesis de derivados de acido 3-amino-tetrahidrofuran-3-carboxilico y uso de los mismos como medicamentos
EP1975165A1 (de) 2007-03-27 2008-10-01 Boehringer Ingelheim Pharma GmbH & Co. KG Substituierte Pyrrolidinamide, deren Herstellung und deren Verwendung als Arzneimittel
US8741890B2 (en) * 2007-11-15 2014-06-03 Boehringer Ingelheim International Gmbh Substituted amides, manufacturing and use thereof as medicaments
JP5562865B2 (ja) 2007-12-17 2014-07-30 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｔｒｐｖ１のイミダゾロ−、オキサゾロ−、及びチアゾロピリミジン・モジュレーター
US7998952B2 (en) 2008-12-05 2011-08-16 Millennium Pharmaceuticals, Inc. Thiolactams and uses thereof
CA2752739A1 (en) * 2009-02-17 2010-08-26 Msd K.K. 1,4-benzodiazepin-2-on derivatives
CN102939103A (zh) 2010-03-30 2013-02-20 西奈山医学院 流感病毒疫苗及其应用
KR20140068205A (ko) 2011-09-20 2014-06-05 마운트 시나이 스쿨 오브 메디슨 인플루엔자 바이러스 백신 및 이의 용도
KR20150104117A (ko) 2012-12-18 2015-09-14 이칸 스쿨 오브 메디슨 엣 마운트 시나이 인플루엔자 바이러스 백신 및 그의 용도
KR101927114B1 (ko) * 2014-02-07 2018-12-10 엑시테라 파마슈티컬스 인코퍼레이티드 치료 화합물 및 조성물
CN105622511B (zh) * 2014-11-03 2018-01-23 北京瑞都医药科技有限公司 一种减肥药物及其制备方法
EP3078378B1 (en) 2015-04-08 2020-06-24 Vaiomer Use of factor xa inhibitors for regulating glycemia
JP7361055B2 (ja) 2018-07-05 2023-10-13 バイエル・アクチエンゲゼルシヤフト 抗菌剤としての置換チオフェンカルボキサミド類及び類縁体
CN111196772B (zh) * 2018-11-16 2022-09-30 沈阳化工研究院有限公司 一种芳酰氨基异丁酰衍生物及其应用
ES2988069T3 (es) 2019-12-20 2024-11-19 Bayer Ag Tieniloxazolonas y análogos
WO2022096542A1 (en) 2020-11-06 2022-05-12 Boehringer Ingelheim International Gmbh 2-[thiophen-2-yl)formamido]-n-(phenyl)-2-methylpropanamide derivatives and the use thereof as medicament
WO2025019631A1 (en) 2023-07-19 2025-01-23 Icahn School Of Medicine At Mount Sinai Immunogenic compositions containing inactivated influenza a virus and cpg oligonucleotide adjuvant and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2248084T3 (es) 1999-06-14 2006-03-16 Eli Lilly And Company Inhibidores de serinproteasa.
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
HUP0300068A2 (en) 2000-03-21 2003-05-28 Smithkline Beecham Corp Protease inhibitors, their preparation, their use and pharmaceutical compositions containing them
DE10063008A1 (de) 2000-12-16 2002-06-20 Merck Patent Gmbh Carbonsäureamidderivate
US20040157828A1 (en) * 2001-05-17 2004-08-12 Ren Xie Protease inhibitors
JP2004300133A (ja) * 2002-11-19 2004-10-28 Takeda Chem Ind Ltd アミン誘導体
AR042064A1 (es) 2002-11-19 2005-06-08 Takeda Pharmaceutical Compuestos de amina con actividad inhibidora de la union al receptor de somastotina
DE10254336A1 (de) * 2002-11-21 2004-06-03 Merck Patent Gmbh Carbonsäureamide
US7250415B2 (en) 2003-06-04 2007-07-31 Bristol-Myers Squibb Company 1,1-Disubstitutedcycloalkyl-, glycinamidyl-, sulfonyl-amidino-, and tetrahydropyrimidinyl-containing diaminoalkyl, β-aminoacids, α-aminoacids and derivatives thereof as factor Xa inhibitors
JP2007537181A (ja) * 2004-05-13 2007-12-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換されたチオフェン−カルボン酸アミド、医薬品の形態におけるこれらの製造及び使用
CA2562714A1 (en) 2004-05-13 2005-11-24 Boehringer Ingelheim International Gmbh Substituted thiophene-2-carboxylic acid amides, the production thereof and the use thereof as drugs
WO2005111029A1 (de) * 2004-05-13 2005-11-24 Boehringer Ingelheim International Gmbh Neue substituierte thiophencarbonsäureamide, deren herstellung und deren verwendung als arzneimittel
DE102004047840A1 (de) * 2004-09-29 2006-03-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Thiophencarbonsäureamide, deren Herstellung und deren Verwendung als Arzneimittel
PE20081834A1 (es) 2006-12-31 2009-01-16 Boehringer Ingelheim Int Proceso para la sintesis de derivados de acido 3-amino-tetrahidrofuran-3-carboxilico y uso de los mismos como medicamentos

Also Published As

Publication number Publication date
UA94910C2 (ru) 2011-06-25
CY1111627T1 (el) 2015-10-07
HRP20110044T2 (hr) 2012-02-29
EP1899330B1 (de) 2010-11-24
JP4768016B2 (ja) 2011-09-07
PL1899330T3 (pl) 2011-05-31
NO20075186L (no) 2008-02-14
TW200738692A (en) 2007-10-16
MX2007016253A (es) 2008-03-07
US9676781B2 (en) 2017-06-13
IL188323A (en) 2013-08-29
CN101213195B (zh) 2012-05-09
CA2613059A1 (en) 2007-01-11
RS51572B (sr) 2011-08-31
ZA200708525B (en) 2009-08-26
PE20070171A1 (es) 2007-03-08
PT1899330E (pt) 2011-01-11
US9062034B2 (en) 2015-06-23
AU2006265216A1 (en) 2007-01-11
ES2357029T3 (es) 2011-04-15
US20130184256A1 (en) 2013-07-18
NO340670B1 (no) 2017-05-29
JP2008546741A (ja) 2008-12-25
ATE489381T1 (de) 2010-12-15
EA015188B1 (ru) 2011-06-30
HK1116190A1 (en) 2008-12-19
IL188323A0 (en) 2008-04-13
TWI392495B (zh) 2013-04-11
SG163540A1 (en) 2010-08-30
EA200702620A1 (ru) 2008-06-30
MY145883A (en) 2012-05-15
EP1899330B9 (de) 2011-11-09
BRPI0612580A8 (pt) 2017-12-26
US20150252050A1 (en) 2015-09-10
US20100216769A1 (en) 2010-08-26
SI1899330T1 (sl) 2011-03-31
EP1899330A1 (de) 2008-03-19
BRPI0612580A2 (pt) 2010-11-23
CN101213195A (zh) 2008-07-02
DE502006008392D1 (de) 2011-01-05
CA2613059C (en) 2013-12-24
WO2007003536A1 (de) 2007-01-11
DK1899330T3 (da) 2011-02-21
NZ565440A (en) 2011-04-29
KR101321722B1 (ko) 2013-10-25
HRP20110044T1 (hr) 2011-02-28
AR054627A1 (es) 2007-07-04
AU2006265216B2 (en) 2011-09-29
KR20080033318A (ko) 2008-04-16

Similar Documents

Publication Publication Date Title
ECSP078058A (es) Nuevas glicinamidas sustituidas, su preparación y su uso como medicamentos
UY30979A1 (es) Pirrolidinamidas sustituidas, su preparacion y su uso como medicamentos
ECSP088824A (es) Prolinamidas sustituidas, su preparación y su uso como medicamentos
ECSP066898A (es) Antagonistas de cgrp seleccionados, procedimiento para su preparación así como su uso como medicamento
UY28773A1 (es) Nuevas amidas de ácidos carboxílicos, su preparación y su uso como medicamentos.
UY28859A1 (es) Antagonistas de cgrp seleccionados, procedimiento para su preparación así como su uso como medicamento
CY1119534T1 (el) Παραγωγα φωσφορου ως αναστολεις κινασης
ECSP12012161A (es) Compuestos en calidad de antagonistas de Bradiquinina-b1
UY30314A1 (es) Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmacéuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
ECSP10010599A (es) Derivados de tienopiridonas como activadores de proteina quinasa activados por amp (ampk)
CR11861A (es) Compuestos organicos
GT200400146A (es) Derivados sustituidos del dioxido de tiazol-benzoisotiazol, procedimiento para su preparacion y su uso
ECSP10010654A (es) Derivados de tienopiridonas como activadores de proteína quinasa activados por amp (ampk)
ECSP109978A (es) Nuevos compuestos
BRPI0606112A2 (pt) 3 - heteroaril - 3 - hidróxi - 2 - amino - propil aminas e compostos relacionados, bem como uso dos mesmos e composição farmacêutica
ECSP10010105A (es) Antagonistas de cgrp
UY28848A1 (es) Antagonistas de cgrp seleccionados, procedimientos para su preparación, y su empleo como medicamentos
UY29767A1 (es) Derivados de benzotiazolonas, procesos para su preparación, composiciones farmacéuticas que los contienen y aplicaciones
GT200500292A (es) Derivados de 2-amido-4-feniltiazol, su preparacion y su aplicacion en terapeutica
CR11273A (es) Derivados-2-ona disustituidos en 3, su preparacion y su aplicacion en terapeutica
CR9407A (es) Tetrahidropiridoazepin-8-onas y compuestos relacionados para el tratamiento de la esquizofrenia
UY31286A1 (es) Antagonistas de receptores de bradiquinina b1. proceso de preparación y aplicaciones.
DOP2007000121A (es) Imidazolidina-2,4-dionas sustituidas con arilaminoarilalquilo, procedimiento para su preparación, medicamentos que comprenden estos compuestos y su uso
UY31643A1 (es) Imidazolidina-2,4-dionas arilcalcogenoarilalquil-sustituidas, procedimiento para su preparación, medicamentos que comprenden estos compuestos y uso de las mismas
ECSP066964A (es) Nuevos beta-agonistas, procedimiento para su preparación y su uso como medicamentos